Equillium, Inc. (NASDAQ:EQ), a biotechnology company with a market capitalization of $25.15 million and current stock price of $0.71, announced today the positive outcomes of their Phase 2 clinical ...

Researchers have used AI to find adalimumab effective for iMCD, highlighting the potential of machine learning in discovering ...

Patients with JIA-associated uveitis who discontinued adalimumab had higher recurrence rates than those who continued the ...

Equillium, Inc. , a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, and ...

Juvenile idiopathic arthritis is the most common chronic systemic disease associated with uveitis in childhood. Uveitis occurs in 11–22% of children with juvenile idiopathic arthritis.1 Due to the ...

After combing through 4,000 existing medications, an artificial intelligence tool helped uncover one that saved the life of a ...

The patient has iMCD, which has a poor survival rate and few treatment options but an AI tool searched through 4,000 ...

Objective To investigate the association between baseline disease activity and the occurrence of flares after adalimumab tapering or withdrawal in patients with rheumatoid arthritis (RA) in sustained ...

aFrancis I Proctor Foundation, University of California San Francisco, San Francisco, CA, USA bDepartment of Ophthalmology, University of California San Francisco, San Francisco, CA, USA cDepartment ...